Lyra Therapeutics, Inc. (LYRA)

Market price: $0.19

6 methods not shown

• EV / EBITDA: EBITDA is non-positive — an EBITDA multiple yields no meaningful enterprise value (loss-making at the EBITDA line)
• EV / Revenue: no multiple band available for EV / Revenue — supplied with market data (peer comps / own history)
• EV / Gross Profit: gross_profit unavailable — cannot form EV / Gross Profit
• P / E: diluted EPS is non-positive — P/E is not meaningful for a loss-making period
• P / B: book value per share is non-positive (negative common equity) — P/B is not meaningful
• DCF (FCFF): base unlevered FCF is non-positive (-25,418,400.62) — nothing to discount; a standard FCFF DCF does not apply

Pre-revenue company — no fundamental valuation is reliable; showing cash position and stage-based peer context only.

We can't show a valuation range for this company yet — we have its financial data, but not a peer group we can stand behind to compare it against, and the methods that apply here price a company against comparable companies.

This security did not trade on 28 October 2026 — the price shown is that day's closing quote. Its last actual trade was 27 October 2026.